WO2019218904A1 - Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation - Google Patents

Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2019218904A1
WO2019218904A1 PCT/CN2019/085914 CN2019085914W WO2019218904A1 WO 2019218904 A1 WO2019218904 A1 WO 2019218904A1 CN 2019085914 W CN2019085914 W CN 2019085914W WO 2019218904 A1 WO2019218904 A1 WO 2019218904A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
compound
alkylene
saturated
Prior art date
Application number
PCT/CN2019/085914
Other languages
English (en)
Chinese (zh)
Inventor
田强
宋帅
王太津
孙启正
赵明亮
李筛
蔡家强
王利春
王晶翼
Original Assignee
四川科伦博泰生物医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 四川科伦博泰生物医药股份有限公司 filed Critical 四川科伦博泰生物医药股份有限公司
Publication of WO2019218904A1 publication Critical patent/WO2019218904A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds

Definitions

  • the present invention relates to a non-natural amino acid derivative, a pharmaceutical composition comprising the same, a process for the preparation thereof and use thereof for preventing or treating a disease or condition associated with arginase activity.
  • Arginase is a dinuclear manganese metalloenzyme with two subtypes: arginase I (ARG-1), which is expressed in the cytoplasm of cells, mainly in the liver; and arginase II ( ARG-2), expressed in mitochondria, is mainly found in the kidney, small intestine, brain, monocytes and macrophages.
  • ARG-2 arginase II
  • L-arginine is mainly metabolized by two pathways: one is hydrolysis to L-ornithine and urea by arginase; the other is oxidized by nitric oxide synthase (NOS). L-citrulline and nitric oxide are produced.
  • arginase not only participates in the ornithine cycle of the liver, but also affects the immune system of humans and mice, and also reduces the production of nitric oxide by hydrolyzing arginine, thereby triggering fibrosis and tissue regeneration, thereby promoting inflammation.
  • arginine deficiency also inhibits T cell immune responses, particularly inflammation-related immune responses, while pathogens can evade immune responses by synthesizing arginase (Nature, 1996, 383, 554-557; Pharm. Pat. Anal ., 2014, 3(1), 65–85; Med. Res. Rev., 2017, 37(3), 475–513).
  • Ubiquitin is a small molecule protein consisting of 76 amino acids and having a highly conserved sequence in eukaryotic cells.
  • the main function of ubiquitin is to label the target protein, and the labeled target protein can be recognized and degraded by the proteasome. This process is called ubiquitin/proteasome system (UPS).
  • UPS ubiquitin/proteasome system
  • the ubiquitin-protein ligase (E3) binds directly to the protein and determines the specificity of degradation.
  • the UPS pathway is an important pathway for protein degradation in cells. UPS plays an important role in many metabolic activities of living cells (such as cell growth, signal transduction, DNA repair, antigen presentation).
  • the UPS process mainly includes the following four steps: 1 activation of ubiquitin: the carboxyl residue of ubiquitin is combined with the thiol group of ubiquitin-activating enzyme E1. This step requires ATP as energy to form a ubiquitin and ubiquitin-activating enzyme. Thioester bond between E1; 2 cross-linking of ubiquitin: E1 transfers activated ubiquitin to ubiquitin-binding enzyme E2 through a lactide process; 3E3 binds ubiquitin complex to target protein: ubiquitin-protein The ligase E3 binds the ubiquitin that binds to E2 to the target protein.
  • the ubiquitin that binds E2 can be directly attached to the target protein; 4 the proteasome completes the degradation: the proteasome recognizes the The labeled target protein, thereby hydrolyzing the target protein into a peptide chain of 7-8 amino acids in length, completes degradation of the target protein.
  • Proteolysis targeting chimeric molecule is a bifunctional molecule that binds to both ubiquitin-protein ligase E3 and target proteins, ubiquitinating target proteins that are not capable of binding to E3. Selective degradation by the UPS system controls the level of target proteins in the cells.
  • the PROTAC molecule consists of three parts: a target protein binding group, a ubiquitin-protein ligase binding group, and a linker.
  • the ubiquitin-protein ligase E3 binding group mainly includes MDM2, cIAP1 (a cytostatic agent of apoptotic protein 1), CRBN (cereblon), and VHL.
  • the present invention provides a PROTAC molecule comprising a group that binds to an arginase, a linker, and a group that binds to an E3 ubiquitin-protein ligase, which degrades arginase by targeting ubiquitination, thereby
  • a disease or condition associated with arginase activity eg, cancer, induced or spontaneous immune disorder, allergic asthma, inflammatory bowel disease, ulcerative colitis, atherosclerosis or hypertension, etc.
  • Some aspects of the invention provide a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof, wherein Said compound has the structure of formula (I):
  • X is a group that binds to arginase
  • Y is a linking group
  • Z is a group that binds to the E3 ubiquitin-protein ligase.
  • compositions comprising a prophylactically or therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate thereof, N- An oxide, an isotopically labeled compound, a metabolite or prodrug, and one or more pharmaceutically acceptable carriers, preferably a solid formulation, a semisolid formulation, a liquid formulation or a gaseous formulation.
  • Another aspect of the invention provides a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or Use of a medicament or a pharmaceutical composition of the invention in the manufacture of a medicament for the prevention or treatment of a disease or condition associated with arginase activity.
  • Another aspect of the invention provides a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or A medicament or a pharmaceutical composition of the invention for use in preventing or treating a disease or condition associated with arginase activity.
  • Another aspect of the invention provides a method of preventing or treating a disease or condition associated with arginase activity, the method comprising administering to an individual in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof , esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs or pharmaceutical compositions of the invention.
  • Another aspect of the invention provides a method of preparing a compound of the invention.
  • alkyl is defined as a linear or branched saturated aliphatic hydrocarbon.
  • C 1-6 alkyl refers to a linear or branched group of 1 to 6 carbon atoms (eg methyl, ethyl, n-propyl, isopropyl, n-butyl, Isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl), which are optionally substituted by one or more (such as 1 to 3) suitable substituents such as halogen Substitution (in this case the group is referred to as "haloalkyl”) (eg CH 2 F, CHF 2 , CF 3 , CCl 3 , C 2 F 5 , C 2 Cl 5 , CH 2 CF 3 , CH 2 Cl or - CH 2 CH 2 CF 3, etc.).
  • haloalkyl eg CH 2 F, CHF 2
  • C 1-4 alkyl refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, Sec-butyl or tert-butyl).
  • alkylene denotes the corresponding divalent group and includes, for example, “C 1-6 alkylene", “C 1-4 alkylene” and the like, and specific examples include, but are not limited to, methylene, ethylene Base, propylene, butylene, pentylene and hexylene.
  • alkenyl refers to a linear or branched monovalent hydrocarbon radical comprising one double bond and having 2 to 6 carbon atoms (“C 2-6 alkenyl”).
  • the alkenyl group is, for example, a vinyl group, a 1-propenyl group, a 2-propenyl group, a 2-butenyl group, a 3-butenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, and 2 Hexyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl.
  • alkenylene is a corresponding divalent group including, for example, "C 2-6 alkenylene", “C 2-4 alkenylene”, and the like, and specific examples thereof include, but are not limited to, vinylidene, arylene A propylene group, a butenylene group, a pentenylene group, a hexylene group, a cyclopentylene group, a cyclohexylene group, and the like.
  • alkynyl refers to a monovalent hydrocarbon radical containing one or more triple bonds, for example having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.
  • alkynylene is a corresponding divalent group including, for example, “C 2-6 alkynylene", “C 2-4 alkynylene” and the like. Examples thereof include, but are not limited to, ethynylene, propynylene, butynylene, pentynylene, and hexynylene.
  • cycloalkyl refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (eg, a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl).
  • cyclooctyl cyclodecyl, or bicyclic, including spiro, fused or bridged systems (such as bicyclo [1.1.1] pentyl, bicyclo [2.2.1] heptyl, bicyclo [3.2.1] octyl Or bicyclo [5.2.0] anthracenyl, decahydronaphthyl, etc.)), which is optionally substituted by one or more (such as 1 to 3) suitable substituents.
  • the cycloalkyl group has 3 to 15 carbon atoms.
  • C 3-6 cycloalkyl refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring of 3 to 6 ring-forming carbon atoms (eg, cyclopropyl, cyclobutyl, cyclopentyl or ring). Hexyl), which is optionally substituted with one or more (such as 1 to 3) suitable substituents, such as methyl substituted cyclopropyl.
  • cycloalkylene means, for example, from 3 to 10 (suitably from 3 to 8, more suitably from 3 to 6) ring carbons.
  • Atomic saturation ie, “cycloalkylene” and “cycloalkyl”
  • unsaturated ie, having one or more double and/or triple bonds in the ring
  • a monocyclic or polycyclic hydrocarbon ring Including but not limited to (sub)cyclopropyl (cyclo), (sub)cyclobutyl (cyclo), (sub)cyclopentyl (cyclo), (sub)cyclohexyl (cyclo), (sub)cycloheptyl ( Ring), (sub)cyclooctyl (ring), (sub)cyclodecyl (ring), (sub)cyclohexenyl (ring), and the like.
  • heterocyclyl As used herein, the terms “heterocyclyl”, “heterocyclylene” and “heterocycle” mean, for example, from 3 to 10 (suitably from 3 to 8, more suitably from 3 to 6) a ring atom, wherein at least one of the ring atoms is a hetero atom selected from N, O and S and the remaining ring atoms are saturated (ie heterocycloalkyl) or partially unsaturated (ie one or more within the ring) Double bond and/or triple bond) cyclic group.
  • 3-10 membered (sub)heterocyclic (yl) has 2 to 9 (eg, 2, 3, 4, 5, 6, 7, 8 or 9) ring carbon atoms and is independently selected from N a saturated or partially unsaturated (sub)heterocyclic ring of one or more (e.g., 1, 2, 3 or 4) heteroatoms of O and S.
  • heterocyclylene group and the heterocyclic ring group include, but are not limited to, (meth)oxiranyl, (i)aziridine, (a) azetidinyl, (sub)oxy Oxetanyl, (i)tetrahydrofuranyl, (di)dioxolinyl, (i)pyrrolidinyl, (i)pyrrolidone, (im)imidazolidinyl, (Asia) Pyrazolyl, (i)pyrroline, (i)tetrahydropyranyl, (i)piperidinyl, (y)morpholinyl, (di)dithianyl, (sub) Thimorpholinyl, (i)piperazinyl or (tri)trithianyl.
  • the group also encompasses bicyclic systems, including spiro, fused or bridged systems (such as 8-azaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2-nitrogen Heterobicyclo[2.2.2]octane, etc.).
  • the heterocyclylene group and the heterocyclic ring group may be optionally substituted by one or more (for example, 1, 2, 3 or 4) suitable substituents.
  • (sub)aryl and “aromatic ring” refer to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated pi-electron system.
  • C 6-10 (sub)aryl” and “C 6-10 aromatic ring” mean an aromatic group containing from 6 to 10 carbon atoms, such as (phenylene)phenyl. (Benzene ring) or (methylene) naphthyl (naphthalene ring).
  • the (sub)aryl and aromatic rings are optionally substituted by one or more (such as 1 to 3) suitable substituents (e.g., halogen, -OH, -CN, -NO 2 , C 1-6 alkyl, etc.) .
  • suitable substituents e.g., halogen, -OH, -CN, -NO 2 , C 1-6 alkyl, etc.
  • heteroaryl and “heteroaryl” refer to a monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms, and which comprise at least one hetero atom which may be the same or different (the hetero atom is, for example, oxygen, nitrogen) Or sulfur), and, in each case, may be benzo-fused.
  • “(sub)heteroaryl” or “heteroaryl” is selected from (i)thienyl, (i)furanyl, (i)pyrrolyl, (i)oxazolyl, (sub)thiazolyl, (i)imidazolyl, (i)pyrazolyl, (i)isoxazolyl, (i)isothiazolyl, (sub)oxadiazolyl, (sub)triazolyl, (sub)thiadiazolyl And their benzo derivatives; or (i)pyridyl, (pyridazinyl), (i)pyrimidinyl, (i)pyrazinyl, (i)triazinyl, etc., and their benzo derivative.
  • aralkyl denotes an aryl or heteroaryl substituted alkyl group, wherein the aryl, heteroaryl and alkyl are as defined herein.
  • the aryl group can have from 6 to 10 carbon atoms
  • the heteroaryl group can have from 5 to 10 ring atoms
  • the alkyl group can have from 1 to 6 carbon atoms.
  • Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.
  • halo or halogen group, as used herein, is defined to include F, Cl, Br or I.
  • substituted means that one or more (eg, one, two, three or four) hydrogens on the designated atom are replaced by the selection of the indicated group, provided that the specified atom is not present at present.
  • the normal valence in the case and the substitution form a stable compound. Combinations of substituents and/or variables are permissible only if such combinations form stable compounds.
  • substituent may be unsubstituted or (2) substituted. If the carbon of the substituent is described as being optionally substituted by one or more of the list of substituents, then one or more hydrogens on the carbon (to the extent of any hydrogen present) may be independently and/or together independently The selected substituents are optionally substituted. If the nitrogen of the substituent is described as being optionally substituted by one or more of the list of substituents, then one or more hydrogens on the nitrogen (to the extent of any hydrogen present) may each independently be independently selected substituent Optionally substituted.
  • each substituent is selected independently of the other.
  • each substituent may be the same or different from another (other) substituent.
  • one or more means 1 or more than 1, such as 2, 3, 4, 5 or 10 under reasonable conditions.
  • a point of attachment of a substituent may come from any suitable position of the substituent.
  • the invention also includes all pharmaceutically acceptable isotopically-labeled compounds which are identical to the compounds of the invention, except that one or more atoms are of the same atomic number but the atomic mass or mass number differs from the atomic mass prevailing in nature. Or atomic substitution of mass.
  • suitable contain a compound of the present invention isotopes include (but are not limited to) isotopes of hydrogen (e.g., deuterium (2 H), tritium (3 H)); isotopes of carbon (e.g.
  • Chlorine isotope eg 36 Cl
  • fluorine isotopes eg 18 F
  • iodine isotopes eg 123 I and 125 I
  • nitrogen isotopes eg 13 N and 15 N
  • oxygen isotopes eg 15 O
  • phosphorus isotope eg 32 P
  • sulfur isotope eg 35 S
  • Certain isotopically-labeled compounds of the invention e.g., those incorporating radioisotopes
  • are useful in drug and/or substrate tissue distribution studies e.g., assays).
  • the radioisotope ruthenium (i.e., 3 H) and carbon-14 (i.e., 14 C) are particularly useful for this purpose because of their ease of incorporation and ease of detection.
  • Substitution with positron emitting isotopes eg, 11 C, 18 F, 15 O, and 13 N
  • PET positron emission tomography
  • Isotopically labeled compounds of the invention can be prepared by replacing the previously employed non-labeled reagents with suitable isotopically labeled reagents by methods analogous to those described in the accompanying routes and/or examples and preparations.
  • the pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent can be substituted with an isotope, for example, D 2 O, acetone-d 6 or DMSO-d 6 .
  • stereoisomer denotes an isomer formed by at least one asymmetric center.
  • a compound having one or more (eg, one, two, three or four) asymmetric centers it can produce a racemic mixture, a single enantiomer, a mixture of diastereomers, and Diastereomers.
  • Specific individual molecules can also exist as geometric isomers (cis/trans).
  • the compounds of the invention may exist as mixtures (often referred to as tautomers) of two or more different forms in a rapidly balanced structure.
  • tautomers include keto-enol tautomers, phenol-keto tautomers, nitroso-oxime tautomers, imine-enamine tautomers Wait. It is to be understood that the scope of the present application covers all such ratios in any ratio (eg, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99). %) isomer or a mixture thereof.
  • Solid lines can be used in this article Solid wedge Virtual wedge
  • the chemical bonds of the compounds of the invention are depicted.
  • the use of solid lines to delineate linkages bonded to an asymmetric carbon atom is intended to include all possible stereoisomers at the carbon atom (eg, specific enantiomers, racemic mixtures, etc.).
  • the use of a solid or virtual wedge to characterize a bond to an asymmetric carbon atom is intended to indicate the presence of the stereoisomers shown.
  • solid and virtual wedges are used to define relative stereochemistry rather than absolute stereochemistry.
  • the compounds of the invention are intended to be stereoisomers (including cis and trans isomers, optical isomers (eg, R and S enantiomers), diastereomers, Geometric isomers, rotamers, conformers, atropisomers, and mixtures thereof exist.
  • the compounds of the invention may exhibit more than one type of isomerism and consist of a mixture thereof (e.g., a racemic mixture and a diastereomeric pair).
  • the invention encompasses all possible crystalline forms or polymorphs of the compounds of the invention, which may be a single polymorph or a mixture of more than one polymorph in any ratio.
  • compositions of the invention may exist in free form for treatment or, where appropriate, in the form of their pharmaceutically acceptable derivatives.
  • pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites or prodrugs, which are administered to a patient in need thereof
  • the compound of the invention, or a metabolite or residue thereof, can be provided directly or indirectly after the drug.
  • a “compound of the invention” it is also intended to encompass the various derivative forms described above for the compound.
  • the pharmaceutically acceptable salts of the compounds of the present invention include the acid addition salts and base addition salts thereof.
  • Suitable acid addition salts are formed from acids which form pharmaceutically acceptable salts.
  • Suitable base addition salts are formed from bases which form pharmaceutically acceptable salts.
  • esters means an ester derived from a compound of the formulae herein, which includes a physiologically hydrolyzable ester (which can be hydrolyzed under physiological conditions to release the free acid or alcohol form of the invention). Compound).
  • the compounds of the invention may also be esters per se.
  • the compound of the present invention may exist in the form of a solvate (preferably a hydrate) wherein the compound of the present invention contains a polar solvent as a structural element of the crystal lattice of the compound, particularly such as water, methanol or ethanol.
  • a polar solvent as a structural element of the crystal lattice of the compound, particularly such as water, methanol or ethanol.
  • the amount of polar solvent, particularly water, may be present in stoichiometric or non-stoichiometric ratios.
  • N-oxides are capable of forming N-oxides because nitrogen requires the use of a lone pair of electrons to oxidize to oxides; those skilled in the art will recognize that N-oxides can be formed.
  • Nitrogen-containing heterocycle Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides.
  • the synthesis of N-oxides for the preparation of heterocyclic and tertiary amines is well known to those skilled in the art and includes the use of peroxyacids such as peroxyacetic acid and m-chloroperoxybenzoic acid (MCPBA), hydrogen peroxide, alkyl groups.
  • MCPBA m-chloroperoxybenzoic acid
  • Hydrogen peroxide such as t-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyl dioxirane oxidize heterocyclic and tertiary amines.
  • metabolites of the compounds of the invention i.e., substances formed in vivo upon administration of a compound of the invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, and the like of the administered compound. Accordingly, the invention includes metabolites of the compounds of the invention, including compounds prepared by contacting a compound of the invention with a mammal for a time sufficient to produce a metabolic product thereof.
  • the invention further includes within its scope prodrugs of the compounds of the invention, which are certain derivatives of the compounds of the invention which may themselves have less or no pharmacological activity, when administered to the body or
  • the above compounds can be converted to the compounds of the invention having the desired activity by, for example, hydrolytic cleavage.
  • prodrugs will be functional group derivatives of the compounds which are readily converted in vivo to the desired therapeutically active compound. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Volume 14, ACS Symposium Series (T. Higuchi and V. Stella).
  • Prodrugs of the invention may, for example, be known by those skilled in the art as “pro-moiety” (e.g., “Design of Prodrugs", H. Bundgaard (Elsevier, 1985))" It is prepared in place of the appropriate functional groups present in the compounds of the invention.
  • the invention also encompasses compounds of the invention containing a protecting group.
  • a protecting group In any process for preparing a compound of the invention, it may be necessary and/or desirable to protect a sensitive group or reactive group on any of the molecules of interest, thereby forming a chemically protected form of the compound of the invention. This can be achieved by conventional protecting groups, such as those described in T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which is incorporated herein by reference.
  • the protecting group can be removed at a suitable subsequent stage using methods known in the art.
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof Wherein the compound has the structure of formula (I):
  • X is a group that binds to arginase
  • Y is a linking group
  • Z is a group that binds to the E3 ubiquitin-protein ligase.
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof Where X is (preferred );
  • A is selected from:
  • U is a C 1-4 alkylene group, preferably a methylene group, an ethylene group, a propylene group or a butylene group;
  • W is selected from the group consisting of: -CR'R"-, -NR"'- and -O-;
  • Ring V is a saturated or partially unsaturated 3-10 membered heterocyclic ring or a saturated or partially unsaturated C 3-10 hydrocarbon ring, preferably a pyrrolidine ring, piperidine ring or piperazine ring;
  • R 1 is selected from the group consisting of -OR a and -NR b R c ;
  • n 1, 2, 3 or 4;
  • j 0 or 1
  • alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, hydrocarbon, heterocyclic, heterocyclic, aryl, heteroaryl and aralkyl groups are each optionally one, two, three Or 4 substituents independently selected from the group consisting of halogen, hydroxy, oxo, cyano, -NH 2 , nitro, fluorenyl, -CO 2 H, -CO 2 C 1-6 alkyl, C 1- 6 alkyl, halo C 1-6 alkyl, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, - NH-C 1-6 alkyl, -N-(C 1-6 alkyl) 2 , -C 1-6 alkylene-OH, -C 1-6 alkylene-CN, -C 1-6 Alkyl-OC 1-6 alkyl, -C
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof ,among them,
  • X is selected from (preferred ).
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where X is selected from:
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where X is selected from:
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where Y is selected from:
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where Y is selected from:
  • the above group is linked to X by a position marked by 1 or 2, and is connected to Z by another position;
  • E is selected from H, -NR'R" (preferably -NH 2 ) and halogen;
  • R d and R e are each independently selected from C 1-6 alkylene, saturated or partially unsaturated C 3-6 cycloalkylene, saturated or partially unsaturated 3-10 membered heterocyclylene, -O- And -NH-;
  • R 5 and R 6 are each independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, 3-10 membered heterocyclyl, hydroxy, -NH 2 , -OC 1-6 alkyl, - NH-C 1-6 alkyl, -N-(C 1-6 alkyl) 2 , C 6-10 aryl, C 6-12 aralkyl (such as benzyl) and 5-14 membered heteroaryl;
  • the alkyl groups are each optionally substituted by 1, 2, 3 or 4 substituents independently selected from the group consisting of halogen, hydroxy, oxo, cyano, -NH 2 , nitro, decyl, -CO 2 H, -CO 2 C 1-6 alkyl, C 1-6 alkyl, halo C 1-6 alkyl, -OC 1-6 alkyl, -O-halogenated C 1-6 alkyl, C 3 -6 cycloalkyl, halo C 3-6 cycloalkyl, -NH-C 1-6 alkyl, -N-(C 1-6 alkyl) 2 , -C 1-6 alkylene-OH, -C 1-6 alkylene-CN, -C 1-6 alky
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where Y is selected from:
  • the above groups are linked to X by the position of the 1 mark, and are connected to Z by the position of the 2 mark.
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof
  • E3 ubiquitin-protein ligase is selected from the group consisting of: von Hippel-Lindau (VHL), CRBN, XIAP, E3A, MDM2, late stage promoting complex (APC), UBR5 (EDD1), SOCS/BC-box /eloBC/CUL5/RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS2, PIAS3 , PIAS4, RANBP2, RNF4, RBX1, SMU
  • the E3 ubiquitin-protein ligase is selected from the group consisting of VHL, CRBN, cIAP-1, MDM2, APC, EDD1, LNXp80, CBX4, HERC1, HERC2, HERC3, HERC4, PIAS1, PIAS2, PIAS3, PIAS4, UBE3A, UBE3B, UBE3C, UBE4A, UBE4B, WWP1, WWP2, CBL, E6, KAP1, N1eL, RNF2, RNF4, RNF8, RNF168, RNF43, SART1, Skp2, TRAF-1, TRAF-2, TRAF-3, TRAF-4, TRAF-5, TRAF-6, UBR5 (EDD1) and ZNRF3.
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof , where Z is:
  • VHL a group that binds to VHL
  • CRBN a group that binds to cIAP1
  • MDM2 a group that binds to MDM2
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof ,among them
  • X is selected from:
  • Y is selected from:
  • the above group is linked to X by the position of 1 mark, and is connected to Z by the position of 2 mark;
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof ,among them
  • X is selected from:
  • Y is selected from:
  • the above group is linked to X by the position of 1 mark, and is connected to Z by the position of 2 mark;
  • X is
  • the invention provides a compound, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug thereof Wherein the compound is selected from the group consisting of
  • compositions and methods of treatment are provided.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate thereof, An N-oxide, an isotopically-labeled compound, a metabolite or prodrug, and one or more pharmaceutically acceptable carriers, preferably a solid formulation, a semi-solid formulation, a liquid formulation or a gaseous formulation.
  • the pharmaceutical composition may further comprise one or more additional therapeutic agents.
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite thereof Or the use of a prodrug or a pharmaceutical composition of the invention in the manufacture of a medicament for the prevention or treatment of a disease or condition associated with arginase activity.
  • the invention provides a compound of the invention, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite thereof Or a prodrug or a pharmaceutical composition of the invention for preventing or treating a disease or condition associated with arginase activity.
  • the invention provides a method of preventing or treating a disease or condition associated with arginase activity, the method comprising administering to an individual in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable compound thereof Salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs or pharmaceutical compositions of the invention.
  • the disease or condition associated with arginase activity is selected from the group consisting of a cardiovascular condition, a sexual dysfunction, a wound healing disorder, a gastrointestinal disorder, an autoimmune disorder, an immune disorder, an infection, a lung disease, Liver disease, inflammation, hemolytic disease and cancer, preferably cancer, colon cancer, breast cancer and lung cancer (including non-small cell lung cancer), renal cell carcinoma, prostate cancer, multiple myeloma, acute myeloid leukemia, Neuroblastoma, glioblastoma or melanoma.
  • “Pharmaceutically acceptable carrier” in the context of the present invention means a diluent, adjuvant, excipient or vehicle with which the therapeutic agent is administered, and which is suitable for contacting humans and/or within the scope of sound medical judgment. Tissues of other animals without excessive toxicity, irritation, allergic reactions, or other problems or complications corresponding to a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, minerals. Oil, sesame oil, etc. Water is an exemplary carrier when the pharmaceutical composition is administered intravenously. It is also possible to use physiological saline and an aqueous solution of glucose and glycerin as a liquid carrier, particularly for injection.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerin, propylene glycol, water, Ethanol and the like.
  • the composition may also contain minor amounts of wetting agents, emulsifying agents or pH buffering agents as needed.
  • Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutically acceptable carriers are as described in Remington's Pharmaceutical Sciences (1990).
  • compositions of the invention may act systemically and/or locally.
  • they may be administered in a suitable route, for example by injection (for example intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, including instillation) or transdermal administration; or by oral, buccal, or oral administration.
  • injection for example intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, including instillation
  • transdermal administration or by oral, buccal, or oral administration.
  • compositions of the invention may be administered in a suitable dosage form.
  • an effective amount refers to an amount of a compound that, to a certain extent, relieves one or more symptoms of the condition being treated after administration.
  • the dosing regimen can be adjusted to provide the optimal desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the urgent need for treatment. It is noted that the dose value can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is to be further understood that for any particular individual, the particular dosage regimen will be adjusted over time according to the individual needs and the professional judgment of the person administering the composition or the composition of the supervised composition.
  • an effective dose will be from about 0.0001 to about 50 mg per kg body weight per day, for example from about 0.01 to about 10 mg/kg/day (single or divided doses). For a 70 kg person, this would add up to about 0.007 mg/day to about 3500 mg/day, such as from about 0.7 mg/day to about 700 mg/day.
  • a dose level that is not higher than the lower limit of the aforementioned range may be sufficient, while in other cases, a larger dose may still be employed without causing any harmful side effects, provided that the larger The dose is divided into several smaller doses to be administered throughout the day.
  • the amount of the compound of the present invention in the pharmaceutical composition may be from about 0.01 mg to about 1000 mg.
  • treating means reversing, alleviating, inhibiting the progression of a condition or condition to which such a term applies or one or more symptoms of such a condition or condition, or Prevention of such a condition or condition or one or more symptoms of such condition or condition.
  • “Individual” as used herein includes human or non-human animals.
  • Exemplary human individuals include a human individual (referred to as a patient) or a normal individual having a disease, such as the disease described herein.
  • “Non-human animals” in the present invention include all vertebrates, such as non-mammals (eg, birds, amphibians, reptiles) and mammals, such as non-human primates, domestic animals, and/or domesticated animals (eg, sheep, dogs). , cats, cows, pigs, etc.).
  • compositions of the invention may also comprise one or more additional therapeutic or prophylactic agents.
  • the structure of the compound was confirmed by nuclear magnetic resonance spectroscopy ( 1 H NMR) or mass spectrometry (MS).
  • the nuclear magnetic resonance spectroscopy ( 1 H NMR) measuring instrument was a Bruker 400 MHz nuclear magnetic resonance apparatus; the solvent was determined to be heavy water (D 2 O), deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or hexamethylene diene.
  • the chemical shift ( ⁇ ) is given in parts per million (ppm).
  • MS mass spectrometer
  • ESI Agilent
  • Example 1 (3R,4S)-3-Amino-1-((3S,21S)-21-amino-3-((2S,4R)-4-hydroxy-2-((4-(4-A) Thiazole-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5,15-dioxo-7,10,13-trioxa-4, Synthesis of 16-diazadocosin-22-acyl)-4-(3-dihydroxyboronic propyl)pyrrolidine-3-carboxylic acid (5)
  • Step 1 (S)-6-(Methoxycarbonyl)-2,2-dimethyl-4,12-dioxo-3,14,17,20-tetraoxa-5,11-diaza Synthesis of hetero-docosane-22-acid (5-2)
  • Step 2 (3S,21S)-21-((tert-Butoxycarbonyl)amino)-3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) Benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5,15-dioxo-7,10,13-trioxa-4,16-diaza Synthesis of Dodecane-22-acid methyl ester (5-3)
  • Step 3 (3S, 21S)-21-((tert-Butoxycarbonyl)amino)-3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) Benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5,15-dioxo-7,10,13-trioxa-4,16-diaza Synthesis of dodecane-22-acid (5-4)
  • Step 4 (3R,4S)-3-azido-1-((3S,21S)-21-((tert-butoxycarbonyl)amino)-3-((2S,4R)-4-hydroxy-2 -((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5,15-dioxo-7,10 ,13-trioxa-4,16-diazadocosin-22-acyl)-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxo Synthesis of Benzene Heteroborolan-2-yl)propyl)pyrrolidine-3-carboxylate (5-5)
  • Step 6 (3R,4S)-3-Amino-1-((3S,21S)-21-amino-3-((2S,4R)-4-hydroxy-2-((4-(4-methyl) Thiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-2,2-dimethyl-5,15-dioxo-7,10,13-trioxa-4,16 Synthesis of bis-azadocosin-22-acyl)-4-(3-dihydroxyborylpropyl)pyrrolidine-3-carboxylic acid (5)
  • the inhibitory activity of the compound on arginase I was evaluated by the following experiment.
  • urea detection reagent (1M H 2 SO 4 , 50 mM H 3 BO 3 , 0.03% Brij35, 2 mM o-phthalaldehyde, 2 mM N-(1-naphthyl)ethylenediamine dihydrochloride) was added. Incubate for 20 min at room temperature with shaking, and read the absorbance at 520 nM (OD 520 nM) by a microplate reader.
  • the inhibitory activity of the compound on the ARG-1 enzyme in the CHOK1-ARG-1 stable cell line was evaluated by the following experiment.
  • the CHOK1-ARG-1 stable cell line (cultured in 1640 cell culture medium) in logarithmic growth phase was inoculated into a 96-well plate at a seeding density of 10,000 cells per well, and cultured overnight with adherent cells; Dilute to a working concentration with PBS solution (containing 20 mM arginine), add 100 ⁇ L of compound dilution to each well in a 96-well plate, and incubate in a cell incubator for 24 hours.
  • the compound of the present invention (for example, the compound of Example 1) has a good inhibitory effect on the ARG-1 enzyme activity in the stable cell line of CHOK1-ARG-1.

Abstract

L'invention concerne un dérivé d'acide aminé non naturel représenté par la formule (I) (X étant un groupe qui se lie à l'arginase ; Y étant un groupe de liaison ; et Z étant un groupe qui se lie à l'ubiquitine-protéine ligase E3), une composition pharmaceutique le comprenant, un procédé de préparation correspondant et une utilisation associée dans la prévention ou le traitement de maladies ou d'états pathologiques associés à l'activité de l'arginase. X-Y-Z (I)
PCT/CN2019/085914 2018-05-18 2019-05-08 Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation WO2019218904A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810479828 2018-05-18
CN201810479828.8 2018-05-18

Publications (1)

Publication Number Publication Date
WO2019218904A1 true WO2019218904A1 (fr) 2019-11-21

Family

ID=68539437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/085914 WO2019218904A1 (fr) 2018-05-18 2019-05-08 Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2019218904A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11420984B2 (en) 2018-02-17 2022-08-23 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2023236926A1 (fr) * 2022-06-07 2023-12-14 天津谷堆生物医药科技有限公司 Dérivé de 4-carbonylamino isoindolin-1-one, composition le comprenant et procédé d'utilisation associé
WO2023236927A1 (fr) * 2022-06-07 2023-12-14 天津谷堆生物医药科技有限公司 Composé de 4-carbonylaminoisoindoline-1,3-dione, son procédé de préparation, composition pharmaceutique et utilisation associées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1606439A (zh) * 2001-12-18 2005-04-13 霍夫曼-拉罗奇有限公司 顺式－2,4,5－三苯基－咪唑啉及其在肿瘤治疗中的应用
CN103249737A (zh) * 2010-10-26 2013-08-14 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐
CN104736569A (zh) * 2012-01-12 2015-06-24 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
WO2017184995A1 (fr) * 2016-04-21 2017-10-26 Bioventures, Llc Composés induisant la dégradation de protéines anti-apoptotiques de la famille bcl-2 et utilisation de ces derniers
CN107428734A (zh) * 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1606439A (zh) * 2001-12-18 2005-04-13 霍夫曼-拉罗奇有限公司 顺式－2,4,5－三苯基－咪唑啉及其在肿瘤治疗中的应用
CN103249737A (zh) * 2010-10-26 2013-08-14 马尔斯公司 作为精氨酸酶抑制剂的硼酸盐
CN104736569A (zh) * 2012-01-12 2015-06-24 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
CN107428734A (zh) * 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
WO2017184995A1 (fr) * 2016-04-21 2017-10-26 Bioventures, Llc Composés induisant la dégradation de protéines anti-apoptotiques de la famille bcl-2 et utilisation de ces derniers

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11420984B2 (en) 2018-02-17 2022-08-23 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US11912727B2 (en) 2018-02-17 2024-02-27 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2023236926A1 (fr) * 2022-06-07 2023-12-14 天津谷堆生物医药科技有限公司 Dérivé de 4-carbonylamino isoindolin-1-one, composition le comprenant et procédé d'utilisation associé
WO2023236927A1 (fr) * 2022-06-07 2023-12-14 天津谷堆生物医药科技有限公司 Composé de 4-carbonylaminoisoindoline-1,3-dione, son procédé de préparation, composition pharmaceutique et utilisation associées

Similar Documents

Publication Publication Date Title
AU2017201536B2 (en) Pyrimidinyl Tyrosine Kinase Inhibitors
CN111801327B (zh) 苯甲酰胺化合物
CA2824599C (fr) Inhibiteurs de l'arginase et leurs procedes d'utilisation
AU2013296627B2 (en) Deuterated ibrutinib
EP3653625B1 (fr) Dérivé à cycle condensé ayant une activité inhibitrice de mgat-2
TW200303860A (en) New compounds
WO2017212329A1 (fr) Composition cliptac
WO2019218904A1 (fr) Dérivé d'acide aminé non naturel, son procédé de préparation et son utilisation
IL215732A (en) Mimetic compounds of reverse rotation, a method for their manufacture and use
JP6805172B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
WO2022068933A1 (fr) Composés et méthodes de traitement de maladies
BG108219A (bg) Бифенилкарбоксамиди, понижаващи липидите
US20130266590A1 (en) Dimeric iap inhibitors
JP2022540332A (ja) Ｂｃｌ－２阻害剤のナノ粒子製剤
WO2023039601A1 (fr) Composés bi-fonctionnels et procédés d'ubiquitination ciblée du récepteur des androgènes
TW202333563A (zh) 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
ES2950965T3 (es) Inhibidor de la familia de cinasas Janus (JAK), preparación del mismo y aplicaciones del mismo
JP2023554062A (ja) 新規アリール－ピリド－ピリミジン－オン誘導体
WO2014062204A1 (fr) Inhibiteurs de métalloprotéinases matricielles et méthodes de traitement de la douleur et d'autres maladies
JP2018505886A (ja) 心血管疾患を治療するための可溶性グアニル酸シクラーゼ（ＳＧＣ）の刺激物質としてのＮ−置換８−［（２，６−ジフルオロベンジル）オキシ］−２，６−ジメチルイミダゾ［１，２−ａ］ピラジン−３−カルボキサミド誘導体
CN115572259A (zh) 芳基磺酰胺化合物及其用途
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19803376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19803376

Country of ref document: EP

Kind code of ref document: A1